It may soon be time to short diabetes and NASH-focused stocks. Maybe not just yet, but turn on a Google Alert for "Revita", "duodenal mucosal resurfacing" and "Fractyl Laboratories" and track developments over the next few months. Here's why. The solution to type II diabetes and non-alcoholic fatty liver disease together could be as simple as a 60-minute minimally invasive, non-pharmacological, painless outpatient procedure. How so?
Judging by the clinical results from a new procedure pioneered by Fractyl Laboratories, the medical community may have been taking an entirely wrongheaded approach to diabetes and fatty liver